“BioJapan 2026” Event and Participation Report About the Opening Ceremony, Keynote Speech and Biopharmaceutical Seminar
“BioJapan 2026” was held for three days from Wednesday, October 7, to Friday, October 9, 2026, at Pacifico Yokohama. As in previous years, “Regenerative Medicine JAPAN 2026” and “healthTECH JAPAN 2026” were held concurrently,In 2026, attendance reached a record high of 22,835 visitors. The number of organizations exhibiting at the trade show was also substantial, and a record 27,813 partnering meetings were held.Furthermore, participants from 40 countries and regions attended, and a large number of international attendees helped energize the venue.The JPMA participated as one of the organizing bodies, and numerous presentations were given by representatives from its member companies. In addition, many companies and organizations set up alliance booths and held meetings with academia and startups, facilitating lively information exchange and networking.
Opening Ceremony and Keynote Speech
Following opening remarks by the Chair of the BioJapan Organizing Committee on behalf of the organizers, congratulatory addresses were delivered by guests from the Ministry of Economy, Trade and Industry; the Ministry of Health, Labor and Welfare; the Ministry of Education, Culture, Sports, Science and Technology; the Japan Business Federation; the British Government; the Lithuanian Government; and Kanagawa Prefecture.This was followed by three presentations, including a keynote address titled “Shaping the Future of Japan’s Biopharmaceuticals Through Co-creation” (delivered by Asuka Miyabashira, Chairperson of the Japan Pharmaceutical Manufacturers Association).
Biopharmaceutical Committee Seminar (Organizer's Seminar)
Challenges and Prospects for Promoting the Use of the Domestic Biopharmaceutical Manufacturing Infrastructure
The JPMA Biopharmaceutical Committee has been consistently hosting organizer seminars at BioJapan. In Japan, through initiatives such as dual-use subsidies, biopharmaceutical CDMOs *1 , and we are now entering a phase where the focus is shifting from “facility development” to “promoting utilization.” Accordingly, for fiscal year 2026, we have planned a session centered on the theme of how to continuously utilize and grow the established domestic manufacturing infrastructure.The sustainable utilization of the domestic manufacturing infrastructure is crucial not only for the stable supply of pharmaceuticals and economic security but also from the perspectives of accumulating domestic technology and talent, as well as economic growth. The next challenge is to transition products—ranging from early-stage development projects by startups to marketed products by pharmaceutical companies—to domestic manufacturing, thereby building a track record of production while increasing facility utilization rates.
In this session, representatives from the Ministry of Economy, Trade and Industry (METI), the Japan Agency for Medical Research and Development (AMED), pharmaceutical companies, and CDMOs shared challenges and future directions for promoting the use of the domestic manufacturing infrastructure from their respective perspectives. Specifically, they discussed the integration of manufacturing and CMC ※2 perspectives from the early stages of drug discovery; the conditions and track record required for domestic CDMOs to be consistently selected; the sharing of experience and insights held by pharmaceutical companies; and the need for a coordinating function to link relevant organizations. These topics were discussed during the panel discussion, fostering a shared understanding.The following is a summary of the content based on the author’s understanding.
- *CDMO: Contract Development and Manufacturing Organization
- *CMC: Chemistry, Manufacturing, and Controls
Panel discussion
Seminar Introduction
Kazuhisa Uchida, Specially Appointed Professor, Graduate School of Science and Technology Innovation, Kobe University
At the outset, Mr. Uchida explained the background for organizing this session, noting that the continued utilization and expansion of the biopharmaceutical CDMO manufacturing infrastructure currently being developed in Japan is crucial from the perspectives of ensuring a stable supply of pharmaceuticals, economic security, and domestic economic growth.On the other hand, it was pointed out that even when including facilities developed with dual-use subsidies, the total capacity of domestic bioreactors is not yet sufficient. A key challenge identified was how to increase bioreactor utilization rates while accommodating products with varying production timelines and required volumes—ranging from early-stage development products by startups to marketed products by pharmaceutical companies.The stated objective of this session was to identify challenges in promoting domestic manufacturing and contract manufacturing, as well as to facilitate discussions among stakeholders regarding the shift in policy support from “facility development” to “promoting utilization.”
Speeches by the Speakers
1) Industrial Expansion and Economic Security through the Utilization of the Domestic Biopharmaceutical and Vaccine Manufacturing Infrastructure
Mr. Kentaro Tanaka, Assistant Director, Biochemical Industry Division, Commerce and Services Group, Ministry of Economy, Trade and Industry
Mr. Tanaka explained that synthetic biology and biotechnology are positioned as priority areas in Japan’s growth strategy, and that it is important to commercialize and manufacture outstanding research results and deliver them to the global market.While Japan possesses a wealth of scientific knowledge, manufacturing technology, and materials and equipment, it was noted that funding, specialized personnel, and manufacturing capabilities are fragmented across different stages of development, preventing individual strengths from being fully leveraged to enhance the competitiveness of the industry as a whole. In particular, the importance of incorporating manufacturing expertise from the early stages of development was emphasized.
Regarding the domestic manufacturing infrastructure, it was noted that through the Dual-Use Initiative—with a total fund of 327.4 billion yen—efforts are underway to establish hubs for vaccines, investigational drugs, formulation and filling, and raw materials and components. These hubs are intended not only to serve as preparedness measures for infectious disease emergencies but also to be utilized for the manufacturing of biopharmaceuticals and other products during peacetime.Mr. Tanaka expressed his hope that pharmaceutical companies would include domestic facilities as candidates in their future development and production plans, and that startups and academic institutions would consult with them early on regarding the manufacture of investigational drugs and other matters.He also explained that since each facility differs in terms of supported modalities, scope of services, production scale, and operational timing, he hopes that through specific consultations, companies will identify the functions that best match their projects.
Furthermore, a strategic direction was outlined to create a virtuous cycle linking research and development to commercialization, manufacturing, market penetration, and subsequent investment, with the goal of establishing Japan’s manufacturing infrastructure to support both domestic and international projects.In the Reiwa 9 fiscal year budget request, a policy was introduced to strengthen support for drug discovery ventures, foundational drug discovery technologies such as AI and digital transformation (DX), manufacturing technologies for regenerative medicine and gene therapy, and the domestic production infrastructure for biopharmaceuticals. Furthermore, it was explained that, in collaboration with the Ministry of Health, Labor and Welfare, efforts would be made to improve the environment to make the Japanese market more attractive.
2) Revitalizing the Domestic Manufacturing Infrastructure During the Development and Mass Production Stages of Biopharmaceuticals
Mr. Hirokazu Shimoda, Coordinator, Japan Agency for Medical Research and Development (AMED)
Mr. Shimoda explained that in order to produce first-in-class and best-in-class pharmaceuticals in Japan, stakeholders must align their objectives and make maximum use of domestic resources.AMED supports approximately 2,700 R&D projects annually, and it was noted that a key challenge in translating research outcomes into practical applications is linking manufacturing process development with various initiatives and support centers.As part of these efforts, it was noted that through AMED IND ENGINE (AND-E), in collaboration with the JPMA, target projects are being selected and optimization and manufacturing process development are being advanced.
Furthermore, it was noted that conducting first-in-human trials in Japan requires both Investigator Sites capable of generating clinical data at an early stage and a manufacturing infrastructure capable of supplying investigational drugs of appropriate quality; thus, the development of domestic CDMOs and the improvement of the clinical trial environment are closely interrelated.It was emphasized that rather than viewing research, the pharmaceutical industry, CDMOs, clinical trials, regulatory review, human resources, and the use of data and AI in isolation, it is necessary to foster collaboration among them and develop a comprehensive strategy that addresses domestic challenges and promotes economic growth.
Regarding the development of the domestic manufacturing infrastructure, it was suggested that building a track record of manufacturing and approvals in collaboration with domestic CDMOs would also contribute to the growth of the pharmaceutical companies themselves. To achieve this, it was deemed important for all stakeholders to share a certain burden and adopt the perspective that each other’s growth leads to their own.Furthermore, it was explained that there is a need to link private-sector initiatives with government investment and to develop a comprehensive vision—involving the Ministry of Economy, Trade and Industry (METI), the Ministry of Health, Labor and Welfare (MHLW), and the Ministry of Education, Culture, Sports, Science and Technology (MEXT)—that leads to the resolution of domestic challenges and industrial growth.
3) Promoting the Use of Domestic Biopharmaceutical CDMOs from the Perspective of Pharmaceutical Companies
Mr. Taishiro Nakagawa, Chairperson of the Policy Subcommittee, Biopharmaceutical Committee, JPMA / Kyowa Kirin Co., Ltd.
Mr. Nakagawa explained, from the perspective of pharmaceutical companies, the challenges involved in continuously maintaining and utilizing the domestic manufacturing infrastructure, which is currently being developed and expanded.While the development of CDMOs in Japan is progressing—and a key strength lies in the ability to apply experience gained overseas in manufacturing, regulatory submissions, and inspection responses to domestic facilities—challenges were identified regarding manufacturing scale and cost-effectiveness to meet global demand, securing talent, and disseminating information to startups and academia.
Pharmaceutical companies select contractors by quantitatively comparing multiple CDMOs based on their respective production strategies and selection criteria. Therefore, it was emphasized that even for newly established domestic CDMOs, it is important to demonstrate how they can compensate for a lack of manufacturing track record through specific mechanisms and innovative approaches, and to provide concrete information that supports decision-making within pharmaceutical companies.Furthermore, it was pointed out that continued reliance on overseas manufacturing not only poses risks to stable supply but also prevents the accumulation of technical expertise and experience in Japan—including in manufacturing, process development, regulatory submissions, and inspection readiness—which could lead to the hollowing out of the country’s technological, human resource, and industrial foundations.
In response to these challenges, the importance of establishing case studies on the utilization of domestic CDMOs and sharing success stories and experiences gained through overseas outsourcing was emphasized.Furthermore, it was noted that pharmaceutical companies should share with startups and ventures—as non-competitive knowledge—the insights they have accumulated in areas such as manufacturing, regulatory submissions, inspection responses, and troubleshooting, while also establishing platforms where pharmaceutical companies, CDMOs, startups, and academia can exchange information.
4) Challenges and Prospects for Promoting the Use of the Domestic Biopharmaceutical Manufacturing Infrastructure: From the CDMO Perspective
Mr. Akira Kase, Director and Executive Officer, Head of the Bio Business Division, FUJIFILM Toyama Chemical Co., Ltd.
Mr. Kase provided an explanation from a CDMO perspective on the challenges and prospects for promoting the use of domestic CDMOs.He explained that the Fujifilm Group supports various modalities across its eight global sites, including the Toyama site, and—under the “kojoX” framework—is standardizing buildings and facilities, quality and IT systems, and personnel and operations across these sites. He noted that this approach enables rapid technology transfer and supply from multiple sites, with the goal of strengthening the supply chain.
The ease of working with a CDMO was categorized into three areas: quality, delivery, and communication. At the Toyama site—which, as a newly established facility, needs to build a track record—efforts are underway to enhance quality and inspection readiness through standardization with global sites, the utilization of proven quality systems and SOPs, and mock inspections.Furthermore, a strategy was outlined to facilitate rapid decision-making through collaboration with R&D, shortening development timelines via the use of digital transformation (DX) and AI, the integrated provision of CRO and analytical services, and business negotiations and program management conducted in Japanese.
Regarding future competitiveness, the importance of leveraging Japan’s manufacturing expertise in biopharmaceutical production was emphasized.It was suggested that, rather than merely ensuring products meet specifications, identifying changes in the manufacturing process as early warning signs of potential issues, investigating their causes, and incorporating these findings into the next production run will lead to minimizing deviations, maximizing yield, and improving cost competitiveness.Ultimately, the view was expressed that Japanese CDMOs should aim not only to meet domestic demand but also to export biopharmaceuticals manufactured in Japan to the rest of the world.
Panel Discussion
During the concluding panel discussion, the following topics were addressed:
- Challenges and Support Measures for Expanding the Use of Domestic CDMOs and Establishing a Track Record of Manufacturing and Approval
- Support Measures to Link Drug Discovery Leads to Domestic Manufacturing and the Formation of a Drug Discovery Ecosystem
- The Roles of Government, Drug Discovery Support Organizations, and Industry in Ensuring the Sustainable Development of the Domestic Manufacturing Infrastructure
Since manufacturing and inspection track records are prioritized in pharmaceutical companies’ selection of production sites, it was emphasized that new domestic CDMO facilities must demonstrate concrete mechanisms to compensate for a lack of track record by leveraging the track records and quality systems of global sites.Furthermore, it was noted that while domestic CDMOs should gradually build a track record starting with early-stage investigational drugs, as latecomers to the market, they have the advantage of learning from the growth trajectories of overseas CDMOs and the experiences of domestic companies that have outsourced overseas, and incorporating these lessons into their services.
To bridge drug discovery leads to domestic manufacturing, it was deemed important to present domestic CDMOs as an option from the early stages of development and to advance CMC and manufacturing process development by backcasting from the quality requirements of the final product.Furthermore, since production scales and facility utilization vary for antibody drugs, cell therapies, viral vectors, and other modalities, it was noted that while modality-specific challenges must be addressed individually, cross-domain collaboration is necessary for common challenges such as GMP compliance, process development, and the use of automation and AI.Furthermore, the importance of incorporating a manufacturing perspective into existing R&D and venture support programs, as well as clearly organizing and disseminating information on available support measures and domestic manufacturing sites, was highlighted.
To ensure the sustainable development of the domestic manufacturing infrastructure, there is a need for a forum where pharmaceutical companies can fairly share their expertise in manufacturing, regulatory submissions, inspections, and troubleshooting as non-competitive information.Furthermore, to collaborate with CDMOs from the early stages of drug discovery, it was noted that funding for manufacturing outsourcing, consulting fees, and the engagement of external experts must be secured as early as the research planning stage; a support mechanism involving collaboration among AMED, venture capital firms, incubation facilities, mentors, and others was also deemed necessary.Furthermore, to foster talent development and connect diverse stakeholders—including those involved in domestically produced raw materials—it was emphasized that we must promote the development and retention of personnel who serve as bridges between these groups and expand opportunities for discussion through platforms such as BioJapan.
Exhibition booth
In 2026, we established a joint task force comprising the R & D Committee, the Biopharmaceutical Committee, and the The Office of Pharmaceutical Industry Research(Policy Research Institute), and proceeded with the planning and preparation of the JPMA exhibition booth. At the booth, we introduced the activities of both committees, the Policy Research Institute, and the JPMA as a whole through posters, handouts, and video presentations.The inclusion of English-language versions of the posters, materials, stamp rally, and videos proved effective, leading to an increase in participants from overseas and improved support for international visitors.In addition, we held a stamp rally again in 2026, presenting commemorative gifts to visitors who stopped by the exhibition booths of the JPMA, as well as those of AMED, the Medical Industry-Academia Collaboration Network Council (medU-net), and Mitsui Fudosan/LINK-J—four organizations involved in the biotech sector.While last year’s stamp rally attracted approximately 200 participants, this year’s event drew over 500. Furthermore, through collaboration with the Public Affairs Committee—including a visit to the JPMA booth by Chairperson Asuka Miyabashira and timely X posts throughout the three days—we believe this ensured a steady stream of visitors to the JPMA booth right up until the final day, further enhancing the effectiveness of our advocacy efforts.
X Post Regarding the Stamp Rally – Day 1
Day 2
Day 3
(Biopharmaceutical Committee, Policy Subcommittee: Motoshi Yamauchi; Director, Regulatory Affairs and Biopharmaceuticals Division: Junko Tsukada)
